273 related articles for article (PubMed ID: 24283931)
1. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis.
Puig L; Strohal R; Husni ME; Tsai TF; Noppakun N; Szumski A; Yang S; Robertson D; Boggs R; Koenig AS
J Dermatolog Treat; 2015 Feb; 26(1):7-15. PubMed ID: 24283931
[TBL] [Abstract][Full Text] [Related]
2. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
[TBL] [Abstract][Full Text] [Related]
3. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.
Boggs RL; Kárpáti S; Li W; Williams T; Pedersen R; Mallbris L; Gniadecki R
BMC Dermatol; 2014 Aug; 14():14. PubMed ID: 25091090
[TBL] [Abstract][Full Text] [Related]
4. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Tsuji W
Arthritis Rheum; 2004 Jul; 50(7):2264-72. PubMed ID: 15248226
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
6. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
[TBL] [Abstract][Full Text] [Related]
7. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
[TBL] [Abstract][Full Text] [Related]
8. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Dunn M; Tsuji W
J Rheumatol; 2006 Apr; 33(4):712-21. PubMed ID: 16463435
[TBL] [Abstract][Full Text] [Related]
9. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
[TBL] [Abstract][Full Text] [Related]
10. Disease characteristics in patients with and without psoriatic arthritis treated with etanercept.
Papp K; Poulin Y; Vieira A; Shelton J; Poulin-Costello M
J Eur Acad Dermatol Venereol; 2014 May; 28(5):581-9. PubMed ID: 23465037
[TBL] [Abstract][Full Text] [Related]
11. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
14. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.
Strand V; Sharp V; Koenig AS; Park G; Shi Y; Wang B; Zack DJ; Fiorentino D
Ann Rheum Dis; 2012 Jul; 71(7):1143-50. PubMed ID: 22258482
[TBL] [Abstract][Full Text] [Related]
15. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
16. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept.
Mease P
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S116-21. PubMed ID: 12463460
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on etanercept in plaque psoriasis and psoriatic arthritis.
Goldsmith DR; Wagstaff AJ
BioDrugs; 2005; 19(6):401-3. PubMed ID: 16392892
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]